Hence, OGA inhibitors have been tested in several clinical trials to target tauopathy and early symptomatic AD, leading to a recent FDA approval of the OGA inhibitor MK-8719 as an orphan drug for tau-driven neurodegenerative disease (Wang et al., 2020). Here, MAPT is linked to tauopathy.